Montelukast added to fluticasone propionate does not alter inflammation or outcomes

Respiratory Medicine

Volumn 104, Issue 10, 2010, Pages 1425-1435

  Djukanović, Ratko ^a   Wilson, Susan J ^a   Moore, Wendy C ^b   Koenig, Steven M ^c   Laviolette, Michel ^d   Bleecker, Eugene R ^b   Davis, W Bruce ^e   Doherty, Dennis E ^f   Olivenstein, Ronald ^g   Israel, Elliott ^h   Kavuru, Mani S ⁱ   Kleerup, Eric ^j   Reilly, Donna S ^k   Yancey, Steven W ^k   Edwards, Lisa D ^k   Stauffer, John L ^l   Dorinsky, Paul M ^m   Jarjour, Nizar N ⁿ  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Laval Hospital and University ^*

^d LAVAL UNIVERSITY   (Canada)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f UNIVERSITY OF KENTUCKY   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ EAST CAROLINA UNIVERSITY   (United States)

^j Pulmonary Medicine Associates Sleep Center   (United States)

^k GLAXOSMITHKLINE   (United States)

^l CV THERAPEUTICS INC   (United States)

^m Teva USA   (United States)

ⁿ UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

more..

Author keywords

Airway inflammation; Asthma; Bronchoscopy; Eosinophils; Fluticasone propionate; Montelukast

Indexed keywords

COLLAGEN; FLUTICASONE PROPIONATE; MONTELUKAST; SALBUTAMOL;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHOSCOPY; BRONCHUS BIOPSY; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LUNG LAVAGE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77956342708     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.04.004     Document Type: Article

References (48)

1. British Thoracic Society Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma Thorax 58 Suppl. 1 2003 1l 94
2. GINA Report Global strategy for asthma management and prevention From the global strategy for asthma management and prevention 2006 Global Initiative for Asthma (GINA) Available from: http://www.ginasthma.org
3. National Asthma Education and Prevention Program Executive summary of the NAEEP expert panel report 3: guidelines for the diagnosis and management of asthma June 2007 National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda, MD NIH Publication No. 07-4051
4. A. Sousa, R. Poston, S. Lane, J. Nakhosteen, and T. Lee Detection of GM-CSF in asthmatic bronchial epithelium and decrease by inhaled corticosteroids Am Rev Respir Dis 147 1993 1447 1461
5. M. Sue-Chu, A. Wallin, S. Wilson, J. Ward, T. Sandstrom, and R. Djukanovic Bronchial biopsy study in asthmatics treated with low and high-dose fluticasone propionate (FP) compared to low-dose FP combined with salmeterol Eur Respir J S30 1999 124
6. P. Barnes How corticosteroids control inflammation: Quintiles Prize lecture 2005 Br J Pharmacol 148 2006 245 254
7. P. Barnes Current issues for establishing inhaled corticosteroids as the anti-inflammatory agents of choice in asthma J Allergy Clin Immunol 101 1998 S427 S433
8. W. Calhoun, B. Lavins, M. Minkwitz, R. Evans, G. Gleich, and J. Cohn Effect of zafirlukast (Accolate) on cellular mediators of inflammation Am J Respir Crit Care Med 157 1998 1381 1389
9. J. Hasday, S. Meltzer, W. Moore, P. Wisniewski, J. Hebel, and C. Lanni Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics Am J Respir Crit Care Med 61 2000 1229 1236
10. M. Laviolette, K. Malmstrom, S. Lu, P. Chervinski, J. Pujet, and I. Peszek Montelukast added to inhaled beclomethasone in treatment of asthma Am J Respir Crit Care Med 160 1999 1862 1868
11. M. Vaquerizo, P. Casan, J. Castillo, M. Perpina, J. Sanchis, and V. Sobradillo Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma Thorax 58 2003 204 210
12. J. Drazen, E. Israel, and P. O'Byrne Treatment of asthma with drugs modifying the leukotriene pathway N Engl J Med 340 1999 197 206
13. R. Green, C. Brightling, S. McKenna, B. Hargadon, N. Neale, and D. Parker Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Eur Respir J 27 2006 1144 1151
14. R. Green, C. Brightling, S. McKenna, B. Hargadon, D. Parker, and P. Bradding Asthma exacerbations and sputum eosinophil counts: a randomized controlled trial Lancet 360 2002 1715 1721
15. E. Pizzichini, M. Pizzichini, R. Leigh, R. Djukanovic, and P. Strek Safety of sputum induction Eur Respir J 20 Suppl. 37 2002 9s 18s
16. N. Jarjour, S. Wilson, S. Koenig, M. Laviolette, W. Moore, and W. Davis Control of airway inflammation maintained at a lower steroid dose with 100/50 μg of fluticasone propionate/salmeterol J Allergy Clin Immunol 118 2006 44 52
17. K.M. Britten, P.H. Howarth, and W.R. Roche Immunohistochemistry on resin sections: a comparison of resin embedding techniques for small mucosal biopsies Biotech Histochem 68 1993 271 280
18. P. Sullivan, D. Stephens, T. Ansari, J. Costello, and P. Jeffery Variation in measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies Eur Resp J 12 1998 811 815
19. W. Moore, J. Hasday, S. Meltzer, P. Wisnewski, B. White, and E. Bleecker Subjects with mild and moderate asthma respond to segmental allergen challenge with similar, reproducible, allergen specific inflammation J Allergy Clin Immunol 108 2001 908 914
20. M. Kraft, R. Martin, S. Lazarus, J. Fahy, H. Boushey, and R. Lemanske Airway tissue mast cells in persistent asthma: predicator of treatment failure when patients discontinue inhaled corticosteroids Chest 124 2003 42 50
21. A. Chetta, A. Foresi, M. Del Donno, G. Bertorelli, A. Pesci, and D. Oliveri Airways remodeling is a distinctive feature of asthma and is related to severity of disease Chest 111 1997 852 857
22. B. Efron, and R. Tibshirani An introduction to the bootstrap 1993 Chapman and Hall London
23. C. Ward Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma Thorax 57 2002 309 316
24. L. Van den Toorn Benefit from anti-inflammatory treatment during clinical remission of atopic asthma Respir Med 99 2005 779 787
25. C. Ward Inter-relationships between airway inflammation, reticular basement membrane thickening and bronchial hyper-reactivity to methacholine in asthma; a systematic bronchoalveolar lavage and airway biopsy analysis Clin Exp Allergy 35 2005 1565 1571
26. F. Capraz The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics Lung 185 2007 89 96
27. I. Pavord Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol J Allergy Clin Immunol 123 2009 1083 1089
28. A. Laitinen Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid Am J Respir Crit Care Med 156 1997 951 958
29. M. Hoshino Inhaled corticosteroid reduced lamina reticularis of the basement by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma Clin Exp Allergy 28 1998 568 577
30. M. Hoshino Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma J Allergy Clin Immuol 104 1999 356 363
31. 2-agonist over three months on airway wall vascular remodeling in asthma Am J Respir Crit Care Med 164 2001 117 121
32. L.-P. Boulet Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma Am J Respir Crit Care Med 162 2000 1308 1313
33. D. Olivieri Effect of short-term treatment with low dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study Am J Respir Crit Care Med 155 1997 1864 1871
34. S. O'Sullivan, M. Akveld, C. Burke, and L. Poulter Effects of addition of montelukast to inhaled fluticasone propionate on airway inflammation Am J Repir Crit Care Med 167 2003 745 750
35. R. Leigh, D. Vethanayagam, M. Yoshida, R. Watson, T. Rerecich, and M. Inman Effects of montelukast and budesonide on airway response and airway inflammation in asthma Am J Respir Crit Care Med 166 2002 1212 1217
36. D. Robinson, D. Campbell, and P.J. Barnes Addition of leukotrienes antagonists to therapy in chronic persistent asthma: a randomized double-blind placebo-controlled trial Lancet 357 2001 2007 2011
37. 2-agonist on asthma pathophysiology: a review of the current evidence Drugs 63 Suppl. 2 2003 35 51
38. R. Djukanovic, J. Wilson, K. Britten, S. Wilson, A. Wall, and W. Roche Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma Am Rev Respir Dis 145 1992 669 674
39. J. Sont, L. Willems, E. Bel, J. van Kreiken, J. Vandenbrouke, and P. Sterke Clinical Control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment Am J Respir Crit Care Med 159 1999 1043 1051
40. N. Ronald, R. Bhalla, and J. Earis The local side effects of inhaled corticosteroids: current understanding and review of the literature Chest 126 2004 213 219
41. Z. Yildrum, T. Ozlu, Y. Bulbul, and H. Bayram Addition of montelukast versus double dose of inhaled budesonide in moderate persistent asthma Respirology 9 2004 243 248
42. D.W. Perng, H.Y. Huang, Y.C. Lee, and R.P. Perna Leukotriene modifier vs inhaled corticosteroid in mild to moderate asthma: clinical and anti-inflammatory effects Chest 125 2004 1693 1699
43. N. Barnes, M. Laviolette, D. Allen, and P. Flood-Page Effects of montelukast compared to double dose budesonide on airway inflammation and asthma control Respir Med 101 2007 1652 1658
44. F.M. Ducharme Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence Br Med J 324 2002 1545 1548
45. F.S. Ram, C.J. Cates, and F.M. Ducharme Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma Cochrane Database Syst Rev 1 2005 CD003137
46. R.H. Green, C.E. Brightling, S. McKenna, and B. Hargadon Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness Eur Respir J 27 2006 1144 1151
47. R. Schleimer Glucocorticoids supress inflammation but spare innate immune responses in airway epithelium Proc Am Thorc Soc 1 2004 222 230
48. C. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 2001 1871 1875